I
Inozyme
Biopharmaceutical company specializing in the development of novel therapeutics to treat rare metabolic diseases
About Inozyme
Inozyme Pharma is a biopharmaceutical company focused on developing innovative treatments for rare diseases characterized by abnormal mineralization, which affects the vasculature, soft tissue, and skeleton. The company primarily targets genetic conditions such as ENPP1 deficiency and ABCC6 deficiency, which lead to severe and often life-threatening complications. Inozyme's lead product candidate, INZ-701, aims to restore the balance of pyrophosphate (PPi) and adenosine, addressing the root causes of these deficiencies. The company's business model revolves around research and development, clinical trials, and eventual commercialization of its therapeutics. Revenue is generated through the successful development and sale of these specialized treatments. Inozyme operates in the rare disease market, serving patients, healthcare providers, and medical researchers. The company is headquartered in Boston, MA, and collaborates with scientists, physicians, and patients to bring its therapies to market.
Source: Dealroom company dataAt a glance
- Status
- Acquired
- Founded
- 2016
- Headquarters
- Boston, United States
- Employees
- 30
- Open positions
- None listed
- Dealroom signal
- 61.5/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Developer Tools, Biotechnology, Spinout, Disease, Metabolism, Biotech and Pharma, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Latest news
Press, funding announcements and product moves mentioning Inozyme.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITIONOther financing | May 2025 | $270M | $270M | BioMarin Pharmaceutical | ↗ |
| IPOOther financing | Jul 2020 | $0 | — | Undisclosed | — |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Inozyme is 250 monthly website visits, down 63.2% over the last three months. Inozyme's team declined 25% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A9 investors entered at this stage
Longitude Capital
Novo Ventures
NEA
Sofinnova Investments
Pivotal Life Sciences
RA Capital Management
Rock Springs Capital
Novo Holdings
Sanofi-Genzyme BioVentures
Other known investors2 additional known investors
BioMarin Pharmaceutical
Yale University
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Inozyme on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Inozyme’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.